ChemFeeds Site Navigation:
Journal Selection:
Search:

99) Metabolic Volume and Clinical Indices (Clinical Cancer Research) Friday July 1st 2016


100) Molecular Profile and FDG-PET Metabolic Volume at Staging in DLBCL--Letter (Clinical Cancer Research) Friday July 1st 2016


101) Ibrutinib Inhibits VLA-4-Dependent Adhesion in CLL--Reply (Clinical Cancer Research) Friday July 1st 2016


102) Letter to the Editor (Clinical Cancer Research) Friday July 1st 2016


103) A PML-I/Thrombospondin-2 Axis Regulates Angiogenesis (Clinical Cancer Research) Friday July 1st 2016


104) Immunosuppressive Effect of Soluble BCMA in MM (Clinical Cancer Research) Friday July 1st 2016


105) The Role of SIRT6 in HCC (Clinical Cancer Research) Friday July 1st 2016


106) Epigenetic Signature for Lung Cancer Diagnosis (Clinical Cancer Research) Friday July 1st 2016


107) Mitochondria in Breast Cancer (Clinical Cancer Research) Friday July 1st 2016


108) Salivary Biomarkers for Oral Cancer Detection (Clinical Cancer Research) Friday July 1st 2016


109) IL-9 in CTCL (Clinical Cancer Research) Friday July 1st 2016


110) Role of Ebp1 in AML Cells (Clinical Cancer Research) Friday July 1st 2016


111) Androgen-Induced Radiosensitization in Prostate Cancer (Clinical Cancer Research) Friday July 1st 2016


112) Cancer-Initiating Cell Targeting Immunotherapy (Clinical Cancer Research) Friday July 1st 2016


113) CEA TCB antibody targeting solid tumors (Clinical Cancer Research) Friday July 1st 2016


114) EGFR Exon 19 Deletion False Negatives (Clinical Cancer Research) Friday July 1st 2016


115) Effects of Immune-Related eQTLs on Cutaneous Melanoma Prognosis (Clinical Cancer Research) Friday July 1st 2016


116) Sym004 Overcomes EGFR-Mediated Cetuximab Resistance (Clinical Cancer Research) Friday July 1st 2016


117) Change in Immune Signature Predicts Response to Trastuzumab (Clinical Cancer Research) Friday July 1st 2016


118) Therapeutic Vaccine for HPV-Infected Women (Clinical Cancer Research) Friday July 1st 2016


119) Phase I Study of Veliparib with Irinotecan (Clinical Cancer Research) Friday July 1st 2016


120) IL6 Polymorphism Predicts Bevacizumab Efficacy (Clinical Cancer Research) Friday July 1st 2016


121) Ixabepilone and Sunitinib in Advanced Solid Tumors (Clinical Cancer Research) Friday July 1st 2016


122) Micrometastasis Volume Determines Recurrence of Stage II CRC (Clinical Cancer Research) Friday July 1st 2016


123) Effect of Abituzumab on Bone Lesions in mCRPC (Clinical Cancer Research) Friday July 1st 2016


124) Adjuvant Immunotherapy in Pediatric Sarcomas (Clinical Cancer Research) Friday July 1st 2016


125) Phase II/III Naptumomab Estafenatox Plus IFN versus IFN in RCC (Clinical Cancer Research) Friday July 1st 2016


126) Tamoxifen Dose Escalation and Therapeutic Drug Monitoring (Clinical Cancer Research) Friday July 1st 2016


127) BIND-014 Nanoparticle in Solid Tumors (Clinical Cancer Research) Friday July 1st 2016


128) NF1-Mutant Lung Cancer (Clinical Cancer Research) Friday July 1st 2016


129) Preclinical Methods in Radiobiology (Clinical Cancer Research) Friday July 1st 2016


130) DNA Repair in Metastasis (Clinical Cancer Research) Friday July 1st 2016


131) Talimogene Laherparepvec in Melanoma (Clinical Cancer Research) Friday July 1st 2016


132) Testosterone in Androgen Receptor Signaling and DNA Repair (Clinical Cancer Research) Friday July 1st 2016


133) Individualized Tamoxifen Dose Escalation (Clinical Cancer Research) Friday July 1st 2016


134) Correction: Pretreatment microRNA Expression Impacting on Epithelial-to-Mesenchymal Transition Predicts Intrinsic Radiosensitivity in Head and Neck Cancer Cell Lines and Patients (Clinical Cancer Research) Wednesday June 15th 2016


135) NDUFA4L2 in HCC Development (Clinical Cancer Research) Wednesday June 15th 2016


136) Epigenetic Regulation of MSX1 in Ovarian Cancer (Clinical Cancer Research) Wednesday June 15th 2016


137) HMGB1 Isoforms in Asbestos Exposure and Mesothelioma (Clinical Cancer Research) Wednesday June 15th 2016


138) IgG Glycome in Colorectal Cancer (Clinical Cancer Research) Wednesday June 15th 2016


139) Strong Prognostic Value of Multiparametric ccfDNA Analysis (Clinical Cancer Research) Wednesday June 15th 2016


140) TIGIT Associates with T-Cell Exhaustion in AML (Clinical Cancer Research) Wednesday June 15th 2016


141) MET DNA Alterations in NSCLC (Clinical Cancer Research) Wednesday June 15th 2016


142) SMAD4 Loss Is Associated with Poor Survival in Colon Cancer (Clinical Cancer Research) Wednesday June 15th 2016


143) Neoadjuvant Chemotherapy and Tumor Immunity (Clinical Cancer Research) Wednesday June 15th 2016


144) CD74 in Stage III Melanoma (Clinical Cancer Research) Wednesday June 15th 2016


145) Plasma Cells, CD8 T Cells, and Survival in Ovarian Cancer (Clinical Cancer Research) Wednesday June 15th 2016


146) PlGF/VEGFR-1 Mediates Obesity-Induced Tumor Progression (Clinical Cancer Research) Wednesday June 15th 2016


147) Targeting NOTCH2 in Bladder Cancer (Clinical Cancer Research) Wednesday June 15th 2016


148) IL18 plus anti-PD-L1 and anti-CTLA-4 Antibodies (Clinical Cancer Research) Wednesday June 15th 2016


149) cfDNA Next-Generation Sequencing in MOSCATO Trial (Clinical Cancer Research) Wednesday June 15th 2016


150) Metabolic Programs Define Biological Features in RCC (Clinical Cancer Research) Wednesday June 15th 2016


151) Clinical Next-Generation Sequencing in Head and Neck Cancer (Clinical Cancer Research) Wednesday June 15th 2016


152) A Novel Tumor-Specific Agent for NIR Fluorescence Imaging (Clinical Cancer Research) Wednesday June 15th 2016


153) Targeted NGS Details DLBCL Divergence and Actionable Targets (Clinical Cancer Research) Wednesday June 15th 2016


154) Biomarkers in Ipilimumab-Treated Melanoma Patients (Clinical Cancer Research) Wednesday June 15th 2016


155) Phase I Study of Linsitinib with Erlotinib (Clinical Cancer Research) Wednesday June 15th 2016


156) GVAX for Recurrent Malignant Glioma (Clinical Cancer Research) Wednesday June 15th 2016


157) Phase I Cancer Study of PI3K-mTOR Inhibitor Apitolisib (Clinical Cancer Research) Wednesday June 15th 2016


158) POLE Mutations in Endometrial Cancer (Clinical Cancer Research) Wednesday June 15th 2016


159) Cisplatin/Veliparib in TNBC and BRCA Mutation-Positive BC (Clinical Cancer Research) Wednesday June 15th 2016


160) PEGylated Hyaluronidase Augments Pancreatic Cancer Treatment (Clinical Cancer Research) Wednesday June 15th 2016


161) Targeting Protein Kinase CK2 (CSNK2) in Cancer (Clinical Cancer Research) Wednesday June 15th 2016


162) TAS-102 for Treatment of Advanced Colorectal Cancer (Clinical Cancer Research) Wednesday June 15th 2016


163) MET Exon 14 Alterations in Lung Cancer (Clinical Cancer Research) Wednesday June 15th 2016


164) Personalized Approach to Diffuse Large B-cell Lymphoma (Clinical Cancer Research) Wednesday June 15th 2016


165) Correction: Hydroxychloroquine Inhibits Autophagy to Potentiate Antiestrogen Responsiveness in ER+ Breast Cancer (Clinical Cancer Research) Wednesday June 1st 2016


166) Correction: Hydroxychloroquine Inhibits Autophagy to Potentiate Antiestrogen Responsiveness in ER+ Breast Cancer (Clinical Cancer Research) Wednesday June 1st 2016


167) MACC1 Induces Tumor Progression in Transgenic Mice (Clinical Cancer Research) Wednesday June 1st 2016


168) MACC1 Induces Tumor Progression in Transgenic Mice (Clinical Cancer Research) Wednesday June 1st 2016


169) DNA Ploidy and PTEN/6q15 Deletions in Prostate Cancer (Clinical Cancer Research) Wednesday June 1st 2016


170) DNA Ploidy and PTEN/6q15 Deletions in Prostate Cancer (Clinical Cancer Research) Wednesday June 1st 2016


171) Role of NDUFA4L2 in Clear Cell Renal Cell Carcinoma (Clinical Cancer Research) Wednesday June 1st 2016


172) B7x Immunosuppression in Human Gliomas (Clinical Cancer Research) Wednesday June 1st 2016


173) Dynamic ER Adaptation to AI Therapy (Clinical Cancer Research) Wednesday June 1st 2016


174) Dynamic ER Adaptation to AI Therapy (Clinical Cancer Research) Wednesday June 1st 2016


175) MYD88 Mutations (L265P vs. Other) in DLBCL (Clinical Cancer Research) Wednesday June 1st 2016


176) Cotargeting AR-Vs and mTOR in CRPC (Clinical Cancer Research) Wednesday June 1st 2016


177) Mutant-Specific TCR Gene Therapy Eradicates Cancer (Clinical Cancer Research) Wednesday June 1st 2016


178) MCT4 as a Potential Therapeutic Target for CRPC (Clinical Cancer Research) Wednesday June 1st 2016


179) Antiangiogenic Activity and Toxicity of Itraconazole Isomers (Clinical Cancer Research) Wednesday June 1st 2016


180) Preclinical Study of Evofosfamide and Topotecan (Clinical Cancer Research) Wednesday June 1st 2016


181) Combination of CART19 and Ibrutinib for Mantle Cell Lymphoma (Clinical Cancer Research) Wednesday June 1st 2016


182) PTEN and p4EBP for pCR Prediction (Clinical Cancer Research) Wednesday June 1st 2016


183) Prostate Cancer Correlation of RSI-MRI and Gleason Grade (Clinical Cancer Research) Wednesday June 1st 2016


184) Phase I Study of MK-2206 and Lapatinib in Combination (Clinical Cancer Research) Wednesday June 1st 2016


185) MK-2206 in Advanced Estrogen Receptor-Positive Breast Cancer (Clinical Cancer Research) Wednesday June 1st 2016


186) Hypoxia and Cancer Stem Cells in HPV-Negative HNSCC (Clinical Cancer Research) Wednesday June 1st 2016


187) Lessons Learned for Dose Selection (Clinical Cancer Research) Wednesday June 1st 2016


188) Rendering the 3 + 3 Design to Rest (Clinical Cancer Research) Wednesday June 1st 2016


189) Nonclinical Safety Evaluations of Oncology Drugs (Clinical Cancer Research) Wednesday June 1st 2016


190) Dose Optimization for Small-Molecule Oncology Drugs (Clinical Cancer Research) Wednesday June 1st 2016


191) Phase I Testing: 60 Years in the Making (Clinical Cancer Research) Wednesday June 1st 2016


192) The Role of BRD4 in PI3K Signaling Resistance (Clinical Cancer Research) Wednesday June 1st 2016


193) Neoantigen for Adoptive T-cell Therapy (Clinical Cancer Research) Wednesday June 1st 2016


194) AKT Inhibitors in the Treatment of Cancer (Clinical Cancer Research) Wednesday June 1st 2016


195) Correction: A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer (Clinical Cancer Research) Thursday May 12th 2016


196) The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy--Response (Clinical Cancer Research) Thursday May 12th 2016


View: prev | next


Mitch Andre Garcia's Chem Feeds 2008-present

Some images have been reproduced by permission of The Royal Society of Chemistry. (RSC' RSS Policy)
Other images have been reproduced with permission of the American Chemical Society. (ACS' RSS Policy)
Few images have been reproduced with pending permission of Wiley-VCH. ()